Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
<h4>Background and objectives</h4>Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of rheumatoid arthritis. Only few clinical trials compare one TNF-blocker to another. Hence, a systematic review...
Guardado en:
Autores principales: | Kalle J Aaltonen, Liisa M Virkki, Antti Malmivaara, Yrjö T Konttinen, Dan C Nordström, Marja Blom |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b4c22d51390b49cba7d9ffc31379170a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.
por: Erik J M Toonen, et al.
Publicado: (2012) -
Circadian timekeeping is disturbed in rheumatoid arthritis at molecular level.
por: Vesa-Petteri Kouri, et al.
Publicado: (2013) -
TNF, SOLUBLE RECEPTORS AND AUTOANTIBODIES TO TNF OF PATIENTS WITH RHEUMATOID ARTHRITIS AND HEALTHY DONORS
por: E. A. Golikova, et al.
Publicado: (2012) -
Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis
por: Francesco Ursini, et al.
Publicado: (2017) -
Safety of etanercept in elderly subjects with rheumatoid arthritis
por: Alfredomaria Lurati, et al.
Publicado: (2009)